Pharmaceuticals and Medical Research (TRBC)

China a sweet spot for U.S. companies’ earnings in second-quarter

China a sweet spot for U.S. companies’ earnings in second-quarter

Published 14/08/2017

Trade tensions between Washington and Beijing may be running high but Corporate America is finding China to be a reliable source of profit growth this year. [more…]

Egypt`s Beltone Financial to launch $1 billion fixed income fund: CEO

Egypt`s Beltone Financial to launch $1 billion fixed income fund: CEO

Published 14/08/2017

Egypt's Beltone Financial will launch a $1 billion investment fund in fixed income instruments in September, its chief executive officer told Reuters on Monday. [more…]

China`s Fosun, Shanghai Pharma say bid for stake in U.S. drugmaker Arbor

China`s Fosun, Shanghai Pharma say bid for stake in U.S. drugmaker Arbor

Published 14/08/2017

A unit of China's Fosun Group and Shanghai Pharmaceuticals Holding Co (601607.SS) are among bidders for a stake in U.S. speciality drugmaker Arbor Pharmaceuticals LLC, the companies said on Monday. [more…]

Vernalis hit by fresh U.S. setback for cough and cold drug

Vernalis hit by fresh U.S. setback for cough and cold drug

Published 07/08/2017

Shares in Vernalis fell more than 15 percent on Monday as the British biotech company backed by fund manager Neil Woodford and his previous employer Invesco announced a fresh setback for a key new drug in the United States. [more…]

DEA proposes cutting production of some opioid painkillers

DEA proposes cutting production of some opioid painkillers

Published 04/08/2017

The U.S. Drug Enforcement Administration (DEA) on Friday proposed a 20 percent reduction in the manufacture of certain commonly prescribed opioid painkillers as well as other controlled substances for next year. [more…]

AstraZeneca gets breakthrough status for blood cancer drug

AstraZeneca gets breakthrough status for blood cancer drug

Published 01/08/2017

FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014.

AstraZeneca said on Tuesday that U.S. regulators had awarded its blood cancer drug acalabrutinib "breakthrough" status for the treatment of patients with mantle cell lymphoma, a rare type of blood cancer.

[more…]

Express Scripts to cover Mylan`s EpiPen, exclude rivals

Express Scripts to cover Mylan`s EpiPen, exclude rivals

Published 31/07/2017

EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016.

Pharmacy benefit manager Express Scripts Holding Co said on Monday it would favor drugmaker Mylan Inc's versions of the EpiPen lifesaving allergy treatment over the allergy auto-injectors of other companies.

[more…]

Slug slime inspires new kind of surgical glue

Slug slime inspires new kind of surgical glue

Published 27/07/2017

FILE PHOTO: A slug hangs from the finger of a gardener in a park in London, Britain April 29, 2016.

Scientists have developed an experimental surgical glue inspired by the mucus secreted by slugs that could offer an alternative to sutures and staples for closing wounds.

[more…]

Scientists find sunscreen potential in Antarctic plants

Scientists find sunscreen potential in Antarctic plants

Published 27/07/2017

Doctor Gustavo Zuniga holds up an Antarctic plant that has molecules that filter the solar radiation and could be used to prevent human DNA damage in Santiago, Chile July 25, 2017.

Scientists in Chile have discovered molecules in two species of Antarctic flowers that protect the plants from solar radiation and could potentially be used in products such as sunscreen for humans and protection for vulnerable crops.

[more…]

EU regulators charge Teva over pay-for-delay drug deal

EU regulators charge Teva over pay-for-delay drug deal

Published 17/07/2017

A building belonging to Teva Pharmaceutical Industries, the world's biggest generic drugmaker and Israel's largest company, is seen in Jerusalem February 8, 2017.

EU antitrust regulators charged Israeli drugmaker Teva (TEVA.TA) (TEVA.N) on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug, putting it at risk of a fine.

[more…]